Amelioration of Uremic Toxin Indoxyl Sulfate by Oral Chito-oligosaccharide in Predialysis Patients : A Randomized Controlled Trial

Effects of Chitosan on Indoxyl Sulfate Reduction in Predialysis Patients : A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220317007

Enrollment

Registered

2022-03-17

Start date

2021-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Indoxyl sulfate level suppression in chronic kidney disease stage IV and IV patients not yet on renal replacement therapy Indoxyl sulfate, chitosan, chronic kidney disease

Interventions

Chitosan 500 mg per capsule Patients took 1 capsule orally once daily after breakfast,Placebo contained starch in capsules with the same appearance as chitosan capsule

Experimental Drug,Placebo Comparator No treatment

Chitosan,Placebo

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: Chronic kidney disease patients with age more than 20 years and stable eGFR less than 20 ml/min/1.73 m2

Exclusion criteria

Exclusion criteria: Anticipated kidney replacement therapy within 3 months Active malignancy Active infection Active autoimmune disease Immunosuppressive state Pregnancy Obstructive or reversible kidney disease

Design outcomes

Primary

Measure	Time frame
Indoxyl sulfate level 4 weeks and 12 weeks high-performance liquid chromatography-mass spectometry method	—

Secondary

Measure	Time frame
Mean eGFR change 4 weeks and 12 weeks CKD-EPI 2012	—

Countries

Thailand

Contacts

Public ContactChumphon Sirisuksakun

Division of Nephrology, Department of Medicine, Phramongkutklao Hospital

domuex@hotmail.com6627639300

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026